Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data . SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 4, p. s405, 2024. DOI: 10.25251/skin.8.supp.405. Disponível em: https://skin.dermsquared.com/skin/article/view/2855. Acesso em: 24 jun. 2025.